In survey, PhRMA member companies highlight impact of IPI on R&D


One of the biggest myths regarding the administration’s proposed International Pricing Index (IPI) Model is that it will have little to no effect on biomedical research and development (R&D). Secretary of Health and Human Services Alex Azar has said that the reduction in R&D couldn’t possibly be more than 1 percent. In contrast, PhRMA estimates that the impact of the model on R&D is much greater with a disproportionately negative effect on innovative medicines, including new medicines that are meeting unmet medical needs for previously untreatable conditions, like some cancers and potential cures for genetic disorders.